Most people with Charcot-Marie-Tooth disease live a normal or near-normal lifespan. CMT is a group of inherited peripheral neuropathies, not a rapidly fatal condition, and the disease itself is rarely a direct cause of death. That said, life expectancy in CMT is a more layered question than the reassuring headline suggests, because certain subtypes carry rare but real risks to the heart and lungs, and the cumulative toll of living with progressive nerve damage affects how well and how independently someone lives across those decades.
Why CMT Is Not a Life-Shortening Disease for Most People
CMT damages the peripheral nerves that control movement and sensation in the limbs. It does not attack the brain, spinal cord, or the motor neurons in the way that diseases like ALS do. A paper comparing CMT and ALS at the molecular level described CMT as “less severe,” noting that “patients have a longer life span, although with a compromised quality of life.”1PubMed Central. Genetic commonalities between rare subtypes of ALS and CMT: insights into molecular mechanisms of neurodegeneration That distinction matters. People newly diagnosed with CMT sometimes fear the worst because the disease is progressive and has no cure, but the trajectory is fundamentally different from the neurodegenerative conditions that shorten life dramatically.
Even the more severe end of the CMT spectrum tends not to be as dire as people expect. Dejerine-Sottas syndrome, which historically implied a worse prognosis than typical CMT1, was studied in a follow-up of 25 patients. Nine of those patients had only moderate disability in adulthood and could still walk at least a kilometer. Ambulant patients in that group ranged in age from 22 to 62 years, and the researchers concluded that DSS “does not imply a severe disability or wheelchair dependency in adult life.”2Journal of Anatomy. Dejerine–Sottas syndrome grown to maturity: overview of genetic and morphological heterogeneity and follow‐up of 25 patients If even a condition considered more serious than standard CMT allows many people to remain on their feet into middle age and beyond, the outlook for the more common subtypes is generally better still.
When CMT Can Affect How Long You Live
The exceptions to the “normal lifespan” rule are uncommon but worth knowing about, especially because they can be monitored and managed if you and your doctors are aware of them.
Respiratory Complications
Some people with CMT develop breathing problems because the disease can affect the phrenic nerve, which controls the diaphragm, or cause changes to the shape of the rib cage. A review of pulmonary function in CMT found that restrictive lung impairment has been linked to phrenic nerve dysfunction, diaphragm weakness, and thoracic cage abnormalities. The same review noted that central sleep apnea can accompany diaphragm dysfunction, while obstructive sleep apnea has been reported in connection with pharyngeal neuropathy.3PubMed. Disorders of pulmonary function, sleep, and the upper airway in Charcot-Marie-Tooth disease These respiratory issues are not universal, but when they occur in severe cases, they can become life-threatening if untreated. Sleep studies and periodic lung function tests are sensible for anyone with pronounced CMT, particularly if scoliosis or diaphragm weakness is present.
Cardiac Involvement
Heart problems in CMT are rare, and researchers still debate how directly the disease’s genetic mutations cause them. A case report described a 50-year-old woman with CMT1A who developed progressive left ventricular dilation starting at age 40 and recurrent heart failure by age 44, with a possible link to the PMP22 gene duplication that causes her neuropathy.4PubMed. Left ventricular hypertrabeculation/noncompaction with PMP22 duplication-based Charcot-Marie-Tooth disease type 1A A broader discussion of cardiac findings in CMT noted that the PMP22 mutation in CMT1A has been associated with heart failure and various rhythm disturbances, and that mutations in the LMNA gene (linked to a less common type 2 form) can lead to cardiomyopathy. However, “the causal relationship between the cardiac abnormalities and mutation is still unclear.”5European Heart Journal – Case Reports. Electrical storm in a patient with Charcot–Marie–Tooth disease treated with radiofrequency ablation and subsequent serious complication of implantable cardioverter defibrillator implantation: a case report
The practical takeaway is not to panic but to be aware. If you have CMT and experience unusual shortness of breath, palpitations, or exercise intolerance beyond what your neuropathy explains, cardiac evaluation is worth pursuing. These complications affect a small minority of CMT patients, but when they do show up, catching them early makes a difference.
Falls, Mobility, and the Risks That Accumulate
Even when CMT does not directly threaten your life, it reshapes the risks you face every day. Foot drop, ankle weakness, and impaired sensation all make falls more likely, and falls in turn carry their own consequences: fractures, head injuries, fear of moving. A cross-sectional study of people with CMT found that about 14% reported falling in the previous 24 hours, and 38% had fallen at least once in the past week.6PubMed Central. Balance Confidence and Falls in Individuals With Charcot–Marie–Tooth Disease: A Cross‐Sectional Observational Study Those numbers are strikingly high. For older adults with CMT, the fall rate combined with age-related bone loss can turn a stumble into a hospital stay, and hospitalizations come with their own cascade of risks.
Low balance confidence also makes people less active, which feeds into a cycle of deconditioning. You move less because you are afraid of falling, and because you move less, you lose the strength and coordination that would have helped prevent falls. Breaking that cycle is one of the most practical things a person with CMT can focus on for long-term health.
Fatigue, Pain, and the Quality-of-Life Gap
The conversation around CMT life expectancy often misses the point that matters most to patients. Living a normal number of years does not mean living those years without burden. A study of over 250 CMT patients found that about 36% experienced abnormal levels of fatigue, compared with roughly 5% of controls.7PubMed Central. Frequency, entity and determinants of fatigue in Charcot–Marie–Tooth disease Patients with high fatigue also had more severe disease overall, greater need for walking aids or ankle braces, and substantially higher rates of anxiety and depression. Over a fifth of those with abnormal fatigue also had scores suggestive of depression, compared to just 3% of CMT patients without pronounced fatigue.
The largest cross-sectional study of quality of life in CMT confirmed that ambulation and hand function are the most impactful issues, but it also surfaced problems that tend to get less clinical attention: pain, body image concerns, and fatigue all significantly affected how people rated their lives. Pain and proximal leg weakness were particularly impactful for women, and hand weakness, difficulty thinking, and decreased social satisfaction worsened with age.8PubMed Central. Quality-of-Life in Charcot Marie Tooth Disease: The Patient’s Perspective The message is that CMT does not just affect your feet and hands. The ripple effects on energy, mood, social participation, and self-image accumulate over years and deserve attention in their own right.
Medications That Can Make CMT Dangerously Worse
One genuinely life-threatening scenario for someone with CMT comes not from the disease itself but from certain medical treatments. Vincristine, a chemotherapy drug used for cancers including childhood tumors, can cause devastating nerve damage in people with CMT, sometimes unmasking a neuropathy that had not yet been diagnosed. A case report described a young child with medulloblastoma who developed severe peripheral polyneuropathy after a relatively low dose of vincristine and was then found to have previously unidentified CMT1A.9PubMed Central. Acute neurotoxicity following vincristine due to Charcot–Marie–Tooth disease in a young child with medulloblastoma
A systematic review of toxic medications in CMT patients concluded that vincristine, and possibly paclitaxel, can trigger atypically severe drug-related nerve damage in people with CMT, and that caution with these drugs is warranted.10PubMed. Toxic medications in Charcot-Marie-Tooth patients: A systematic review If you have CMT or a family history of unexplained neuropathy, make sure any oncologist, surgeon, or anesthesiologist treating you knows about it before prescribing neurotoxic agents. Various organizations maintain lists of medications considered risky for people with CMT, and carrying that information is a concrete step that can prevent a genuinely dangerous situation.
How CMT Progresses Over a Lifetime
CMT is progressive, but the pace varies enormously depending on the genetic subtype, the specific mutation, and individual factors that researchers are still working to understand. In children and adolescents, a longitudinal study in Brazil tracked disease progression over two years using a pediatric scoring system. The total score increased by an average of about 4.5 points over that period, with measurable deterioration in hand dexterity, sensation, and gait visible within just one year. The CMT1A subgroup specifically showed an average annual increase of 2 points.11PubMed Central. Longitudinal assessment of natural disease progression in Brazilian children and adolescents with Charcot-Marie-Tooth disease A separate study of childhood-onset demyelinating CMT in Brazil found that almost all patients in the cohort had moderate or severe scores, with CMT1B showing the highest severity.12PubMed Central. Clinical and Genetic Aspects of Childhood-Onset Demyelinating Charcot-Marie-Tooth’s Disease in Brazil
For adults, the progression tends to be slow enough that many people adapt year by year, compensating with braces, adjusted footwear, or changes in activity. But “slow” is not the same as “trivial.” Over decades, the accumulation of lost strength and sensation changes what daily life looks like. Some people remain fully ambulatory into old age. Others need a wheelchair by midlife. Predicting where any individual will land on that spectrum is one of the hardest problems in CMT care.
Researchers are making progress on biomarkers that could help. A study of blood samples from CMT patients found that levels of neurofilament light chain (a protein released when nerve fibers are damaged) correlated with disease severity scores.13PubMed Central. Evaluating plasma biomarkers NfL, GFAP, GDF15, and FGF21 as indicators of disease severity in Charcot-Marie Tooth patients Separately, a group studying skin biopsies in CMT1A patients identified a set of genetic markers that could distinguish mildly from severely affected patients with about 90% sensitivity, and whose expression changed over time in a way that tracked with whether the disease was getting worse.14PubMed Central. Biomarkers predict outcome in Charcot Marie Tooth Disease 1A MRI-based measurements of nerve diameter and tissue properties in nerve roots also show promise as markers of severity and progression.15PubMed Central. Nerve Diameter and DTI Parameters Maybe Potential Markers for Clinical Trial in Patients With Charcot-Marie-Tooth Disease Type 1A None of these is routine in clinical practice yet, but the ability to predict who will progress quickly could eventually shape treatment decisions and clinical trial enrollment.
What You Can Do to Stay Functional
There is no drug that slows CMT progression today, but that does not mean nothing helps. Orthopedic management is the backbone of CMT care. Custom footwear and ankle-foot orthoses remain the first-line approach for the characteristic high-arched, inward-turning foot deformity that most CMT patients develop.16PubMed Central. Charcot-Marie-Tooth Cavovarus Foot: Current Concepts and Emerging Strategies for Deformity Correction When bracing is no longer enough, reconstructive surgery can correct foot alignment, improve walking, and reduce dependence on external supports. One surgical protocol involving tendon transfers and bone realignment showed functional improvement while preserving joint mobility, potentially delaying or avoiding the more drastic option of fusing the hindfoot joints.17Journal of the Foot & Ankle. Efficacy of triple surgery for cavovarus foot in Charcot-Marie-Tooth disease
Exercise deserves a dedicated mention because many CMT patients have been told at some point to avoid overexerting their muscles, leaving them unsure about what is safe. A study of resistance training in CMT patients found that participants who exercised increased their muscle fiber diameter, gained strength, and improved their performance on daily-living tasks.18PubMed. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease Moderate, supervised strength training appears to be safe and beneficial, though the specifics should be tailored to each person’s level of weakness. Maintaining as much strength and cardiovascular fitness as possible protects against the secondary risks, like falls and deconditioning, that accumulate over a lifetime with CMT.
Gene Therapy and the Research Horizon
The most exciting developments in CMT research are in gene-based treatments, though none has reached patients yet. Because the most common form, CMT1A, is caused by having an extra copy of the PMP22 gene, the therapeutic logic is to dial PMP22 expression back to normal levels. A review of the current treatment landscape noted that gene silencing techniques, gene editing tools, and stem cell approaches have all shown promise in animal models, but none has entered clinical trials in humans. Concerns about long-term safety, off-target effects, and the challenges of delivering therapies to peripheral nerves remain unresolved.19PubMed Central. The current status of Charcot-Marie-Tooth disease type 1 A treatment
A separate review of gene therapy development across multiple CMT types summarized the progress as having achieved “preclinical successes” with “translational challenges” still ahead.20PubMed Central. Developing a gene therapy for Charcot-Marie-Tooth disease: progress and challenges For CMT2A, which involves mutations in the MFN2 gene affecting mitochondrial function, a recent preclinical study reported that delivering extra copies of normal MFN2 into the nervous system of mice with CMT2A reversed molecular signs of disease and restored motor function, even when treatment was started after symptoms had appeared.21bioRxiv. Gene therapy-mediated overexpression of wild-type MFN2 improves Charcot-Marie-Tooth disease type 2A That last detail, the ability to rescue function after symptom onset rather than only prevent it, is particularly encouraging. It suggests that even if therapies arrive years from now, they might still help people who are already living with the disease.
For now, the realistic timeline for approved gene therapies in CMT is measured in years, not months. But the field is moving, and the number of groups actively working on it has grown substantially. If the therapeutic pipeline delivers even a partial treatment for the most common subtypes, the conversation about CMT will shift from managing an inevitable decline to potentially slowing or stopping it.
Reproductive Decisions and Family Planning
Because CMT is inherited, the question of life expectancy often surfaces alongside questions about having children. Most common forms of CMT follow an autosomal dominant pattern, meaning a parent with CMT has a 50% chance of passing the mutation to each child. The severity that child experiences, however, is not predictable from the parent’s course. Two people in the same family with the identical mutation can have markedly different levels of disability. Genetic counseling can clarify the inheritance pattern for your specific subtype, outline reproductive options like preimplantation genetic testing, and help frame the decision in terms of what the science actually shows rather than worst-case scenarios. The decision itself is deeply personal, but it helps to make it with accurate information rather than fear about a shortened life that, for most CMT subtypes, the data simply does not support.